DUBLIN--(BUSINESS WIRE)--The "Global Psychiatry Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
The Global Psychiatry Partnering 2012-2018: Deal trends, players and financials report provides an understanding and access to the Psychiatry partnering deals and agreements entered into by the world's leading healthcare companies.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Psychiatry disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Psychiatry deals.
The report presents financial deal terms values for Psychiatry deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Report scope
- Trends in Psychiatry dealmaking in the biopharma industry since 2012
- Analysis of Psychiatry deal structure
- Access to headline, upfront, milestone and royalty data
- The leading Psychiatry deals by value since 2012
Available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Psychiatry dealmaking
Chapter 3 - Financial deal terms for Psychiatry partnering
Chapter 4 - Leading Psychiatry deals and dealmakers
Chapter 5 - Psychiatry contract document directory
Chapter 6 - Psychiatry dealmaking by therapeutic target
